Trade Report: The 6,500 Shares of Vertex Pharmaceuticals Inc. (VRTX) Stock are sold by Joshua S. Boger

The 6,500 Shares of Vertex Pharmaceuticals Inc. (VRTX) Stock are sold by Joshua S. Boger

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 12th. The shares were sold at an average price of $81.14, for a total value of $527,410.00. Following the transaction, the director now owns 274,725 shares of the company’s stock, valued at approximately $22,291,186.50. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) opened at 80.50 on Tuesday. Vertex Pharmaceuticals Inc. has a 12 month low of $75.90 and a 12 month high of $134.71. The firm’s market cap is $19.95 billion. The firm’s 50-day moving average price is $89.83 and its 200-day moving average price is $89.91.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.03. Vertex Pharmaceuticals had a negative return on equity of 12.34% and a negative net margin of 17.77%. The company had revenue of $431.61 million for the quarter, compared to analysts’ expectations of $428.08 million. During the same period in the prior year, the firm earned ($0.54) earnings per share. The firm’s revenue was up 159.9% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals Inc. will post $0.89 earnings per share for the current year.

Several equities analysts have weighed in on VRTX shares. Zacks Investment Research cut Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 27th. Jefferies Group reaffirmed a “buy” rating and issued a $107.00 price objective (up from $102.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, July 31st. Citigroup Inc. initiated coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 13th. They issued a “market perform” rating for the company. They noted that the move was a valuation call. Leerink Swann reaffirmed an “outperform” rating and issued a $113.00 price objective on shares of Vertex Pharmaceuticals in a research note on Thursday, September 15th. Finally, Vetr raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $94.50 price objective for the company in a research note on Monday, June 27th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $117.60.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VRTX. Cleararc Capital Inc. boosted its position in Vertex Pharmaceuticals by 0.6% in the first quarter. Cleararc Capital Inc. now owns 6,028 shares of the pharmaceutical company’s stock worth $479,000 after buying an additional 33 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of Vertex Pharmaceuticals by 1.8% in the first quarter. UBS Asset Management Americas Inc. now owns 2,953,715 shares of the pharmaceutical company’s stock valued at $234,790,000 after buying an additional 50,977 shares during the last quarter. Edmond DE Rothschild Holding S.A. boosted its stake in shares of Vertex Pharmaceuticals by 44.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 188,514 shares of the pharmaceutical company’s stock valued at $14,985,000 after buying an additional 58,300 shares during the last quarter. Scotia Capital Inc. boosted its stake in shares of Vertex Pharmaceuticals by 243.8% in the first quarter. Scotia Capital Inc. now owns 9,541 shares of the pharmaceutical company’s stock valued at $759,000 after buying an additional 6,766 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 23.1% in the first quarter. Lazard Asset Management LLC now owns 960,230 shares of the pharmaceutical company’s stock valued at $76,327,000 after buying an additional 180,389 shares during the last quarter. Institutional investors own 96.17% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Related posts

Leave a Comment